Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Award of licensing option in the North Celtic Sea

14 Nov 2012 07:00

RNS Number : 0524R
Fastnet Oil & Gas PLC
14 November 2012
 



14 November 2012

Fastnet Oil & Gas plc

Award of licensing option in the North Celtic Sea

 

Fastnet Oil & Gas plc ("Fastnet" or the "Company") (AIM: FAST, ESM: FOI) the E&P company focused on near term exploration acreage in the Celtic Sea and Africa, is pleased to announce that it has been notified by the Petroleum Affairs Division of the Irish Department of Communications, Energy and Natural Resources (the "Department") that it has been awarded a licensing option ("Licensing Option") of part blocks 49/7, 49/8, 49/9, 49/12 and 49/13 in the North Celtic Sea, offshore Ireland. The Licensing Option commences from 15 November 2012 until 14 May 2014.

 

Highlights

§ 18 month licensing option requiring the re-mapping of the area and review of existing seismic data with value enhancing 3D seismic acquisition anticipated

§ Potential to extend the Licensing Option by a further 18 months subject to a satisfactory work programme being agreed with the Department

§ Hydrocarbon-bearing sections extend over a gross interval of up to 700 feet in early wells drilled by marathon in 1974 and 1986

§ Oil and gas-bearing reservoirs developed at several separate levels

 

Details of the Licensing Option

The application for the Licensing Option was made jointly by Fastnet, Carob Limited ("CRB"), a consultant to Fastnet, and Petro-Celtex Consultancy Limited ("PCX"), a company established by Paul Griffiths, now Managing Director of Fastnet. The Licensing Option acreage lies in water depths of up to 100 metres in the North Celtic Sea basin. Marathon Oil Corporation ("Marathon") drilled two wells in the area of the Licensing Option in 1974 (49/13-1) and 1986 (49/13-2).

49/13-1 tested a shallow anticline generated by Tertiary basin inversion that could be identified at the time on the existing poor quality 2D seismic data. The well encountered oil-bearing Purbecko-Wealden sands over a gross interval of 300 feet, stratigraphically equivalent to the hydrocarbon-bearing reservoirs tested in the Barryroe oil field to the southwest. The interval was tested by Marathon but it did not flow oil as the test tool became plugged with sand. Later seismic mapping, based on new 2D seismic acquisition in 1985 by Ardmore Exploration Limited ("Ardmore"), Marathon's partner in the 49/13-2 well, showed that the well was drilled significantly downdip from the crest of the structure.

Marathon and Ardmore drilled 49/13-2 in 1986 to test a down-faulted Upper Jurassic structural trap analogous to that successfully tested by Gulf Oil in 1983 (49/9-2, Helvick oil discovery). The well encountered oil in the Upper Jurassic over a gross interval of approximately 700 feet. Marathon tested the well but failed to flow any significant amounts of oil due to the low gravity of the oil.

The large vertical extent of the hydrocarbon-bearing sections seen in the above two wells provides encouragement that significant in-place oil resources may exist within the area of the Licensing Option.

 

Work program

Fastnet has agreed a work program for the initial 18 month period of the Licensing Option (the "Initial Phase") which is to reprocess and interpret existing 2D seismic data and to undertake desktop studies designed to confirm the quality and gravity of the oil encountered in both wells and to determine potential reservoir deliverabilities.

Subject to results, Fastnet would move to agree a new and expanded work program with the Department to acquire 3D seismic data during an 18 month extension to the Initial Phase in order to better define the size of the traps tested by the wells.

 

Holders of Licensing Option

Pursuant to a participation and compensation agreement ("Agreement") entered into by Fastnet, CRB and PCX prior to submission of the joint-application for the Licensing Option the holders of the Licensing Option are as follows:

Holder

Interest

Fastnet Oil and Gas (Ireland) Ltd (Operator)

85%

CRB

7.5%

PCX

7.5%

 

Terms of the Agreement

The Licensing Option was originally identified by CRB and PCX. Accordingly and pursuant to the terms of the Agreement, Fastnet has agreed to pay to CRB and PCX certain one-off and consultancy fees both in relation to both the making of the joint application and in relation to ongoing technical advisory services.

In addition, Fastnet has granted the following warrants over ordinary shares in the capital of the Company, which shall be exercisable for a period of three years from 9 November 2012 at 17 pence per share:

 

Holder

Warrants granted

CRB

1,333,333

PCX

666,667

 

In addition, Fastnet has granted CRB and PCX a total 15% (7.5% each) carried interest, during the Initial Phase. The value of the carried interest is capped at €30,000 (€15,000 each) for CRB and PCX.

In the event that, by unanimous agreement of Fastnet, CRB and PCX, it is necessary to increase the budget for the Initial Phase beyond the €30,000 cap for CRB and PCX then CRB and PCX may, at their sole discretion pay their proportion of costs or have their interest in the Licensing Option diluted accordingly.

Production bonus

In the event that a well is drilled by the parties to this Licensing Option leading to commercial production of oil, gas and/or condensate, then CRB and PCX shall be awarded a production bonus amounting to the sum of €400,000, being split €200,000 to each of CRB and PCX.

This production bonus shall be paid by Fastnet and/or its successors or assignees after a period of 12 months following the date of first commercial production.

 

Cathal Friel, Chairman of Fastnet commented:

"We are delightedto have strengthened our portfolio of material prospects in Ireland with the award of another Licensing Option offshore Ireland. Early drilling by Marathon confirmed the oil potential of this area of the North Celtic Sea. The application of new 3D seismic acquisition and processing technology is required to further define the extent of the structural traps and the likely size of potential oil resources."

For further information, please contact:

 

Fastnet Oil & Gas plc

Cathal Friel, Chairman

 

+353 (1) 644 0007

Shore Capital

(Nominated Adviser & Joint Broker)

Nomad

Bidhi Bhoma

Edward Mansfield

 

Corporate Broking

Jerry Keen

+44 (0) 20 7408 4090

Davy

(ESM Adviser & Joint Broker)

John Frain

Brian Garrahy

Roland French

 

+353 (1) 679 6363

FTI Consulting

Edward Westropp

+44 (0) 207 831 3113

 

 

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEDGBDBCDBBGDX
Date   Source Headline
6th Jan 20225:30 pmRNSAmryt Pharma
6th Jan 20227:00 amGNWKey Dates for AIM Delisting
4th Jan 202212:00 pmGNWThe Lancet Diabetes & Endocrinology Publishes Positive Results for the MPOWERED Phase 3 Trial for Mycapssa® (oral octreotide) in Acromegaly Patients
4th Jan 20227:00 amGNWTotal Voting Rights
1st Dec 20217:00 amGNWTotal Voting Rights
30th Nov 20217:00 amGNWDirector/PDMR Shareholding
23rd Nov 202112:00 pmGNWAmryt Provides Update on Regulatory Review Process for Oleogel-S10
22nd Nov 20217:00 amGNWAmryt Announces the Cancellation of Admission of its Ordinary Shares to Trading on AIM
3rd Nov 202111:00 amGNWAmryt Reports Strong Q3 2021 Results
1st Nov 20211:00 pmGNWTotal Voting Rights
1st Nov 20217:00 amRNSAmryt Supports Acromegaly Awareness Day
22nd Oct 20217:00 amRNSAmryt Supports Global EB Awareness Week 2021
20th Oct 202112:00 pmGNWAmryt to Report Q3 2021 Results and Host Conference Call & Webcast on November 3
19th Oct 202112:00 pmGNWAmryt Announces New Patents for Oleogel-S10 and Mycapssa®
23rd Sep 202112:00 pmRNSAmryt Supports Global FH Awareness Day
13th Sep 202112:00 pmGNWAmryt Raises Full Year 2021 Revenue Guidance to $220M - $225M
1st Sep 20217:00 amGNWTotal Voting Rights
19th Aug 20217:00 amGNWAmryt Issues Ordinary Shares and Total Voting Rights
13th Aug 20211:23 pmRNSHolding(s) in Company - Replacement
11th Aug 202111:30 amRNSHoldings in Company
11th Aug 202110:36 amRNSHolding(s) in Company
10th Aug 20212:20 pmGNWDirector/PDMR Shareholding
10th Aug 20219:53 amRNSHolding(s) in Company
9th Aug 202112:00 pmGNWAmryt Virtual Capital Markets Event - September 13, 2021 – 1000-1200 EDT
6th Aug 202112:00 pmGNWAmryt Reports Record Q2 2021 Results and Raises FY 2021 Guidance
5th Aug 20213:50 pmGNWAmryt Successfully Completes Acquisition of Chiasma, Inc., Board Appointments, Issues Ordinary Shares and Total Voting Rights
28th Jul 20213:00 pmGNWResult of General Meetings
12th Jul 202112:00 pmGNWAmryt to Report Q2 2021 Results and Host Conference Call & Webcast on August 6
28th Jun 202112:00 pmGNWPublication of Circular to Amryt Shareholders in relation to the acquisition of Chiasma, Inc., and posting of Annual Report and Notices of General Meetings
15th Jun 202111:45 amGNWAmryt Pharma Announces Filing of Preliminary Registration Statement on Form F-4 in Connection with Its Proposed Acquisition of Chiasma, Inc.
7th Jun 202112:00 pmGNWFDA confirms NDA for Oleogel-S10 will not require an Advisory Committee Meeting
3rd Jun 20217:00 amGNWFDA Grants Priority Review for New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
2nd Jun 20211:30 pmGNWAmryt Announces FDA Acceptance of New Drug Application for Oleogel-S10 for the Treatment of Epidermolysis Bullosa
5th May 20214:41 pmRNSSecond Price Monitoring Extn
5th May 20214:35 pmRNSPrice Monitoring Extension
5th May 202112:05 pmGNWAmryt Reports Record Q1 2021 Financial and Operating Results
5th May 202112:00 pmGNWAmryt Pharma to Acquire Chiasma, Inc. to Further Strengthen Global Leadership in Rare and Orphan Diseases
15th Apr 202112:00 pmGNWAmryt to Report Q1 2021 Results and Host Conference Call & Webcast on May 5
6th Apr 20217:00 amGNWAmryt Announces the Appointment of Sheila Frame as President Americas
31st Mar 202111:00 amRNSAmryt Supports World Lipodystrophy Day
31st Mar 20217:00 amGNWAmryt Submits a New Drug Application to the US Food and Drug Administration for Oleogel-S10* (Filsuvez®)
30th Mar 20217:00 amGNWAmryt Announces Results from an Investigator Sponsored Study of Lomitapide in FCS
29th Mar 20217:00 amGNWAmryt Announces Validation of its MAA by the EMA for Oleogel-S10* (Filsuvez®)
23rd Mar 20217:00 amGNWAmryt Receives Positive Feedback from the FDA on the Path Forward for Myalept® (metreleptin) Indication in Partial Lipodystrophy
22nd Mar 20217:00 amGNWAmryt Receives Reimbursement Approval from the French Ministry of Social Affairs and Health for Myalepta® (metreleptin)
15th Mar 202110:00 amGNWDirector/PDMR Shareholding
12th Mar 20217:00 amGNWExercise of Options and Total Voting Rights
11th Mar 202111:30 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
8th Mar 20216:00 pmGNWDirector/PDMR Shareholding
8th Mar 20217:00 amGNWAmryt and Medison Pharma Sign Distribution Agreement for Myalepta® (metreleptin) in Canada

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.